Cargando…

Clinical efficacy and tolerability of Esketamine: a case series

INTRODUCTION: Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD). The intranasal spray system appears to be more manageable than intravenous ketamine infusion. It contains ketamine’s S- isomer whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passani, C., Ragone, N., Congedo, C.M., Barbini, B., Zanardi, R., Cavallini, M.C., Colombo, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568066/ http://dx.doi.org/10.1192/j.eurpsy.2022.2294

Ejemplares similares

Accelerated repetitive transcranial magnetic stimulation (ATMS) vs standard repetitive transcranial magnetic stimulation (RTMS) in the treatment of major depressive episodes. preliminary data of a randomized, single-blind, controlled trial
por: Prato, M., et al.
Publicado: (2023)

Good Practice for Treatment-Resistant Depression during SARS CoV – 2 outbreak: are ketamine infusions an effective alternative for TRD patients? A case series
por: Ragone, N., et al.
Publicado: (2023)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Manic patients and sleep management: the role of polysomnography in clinical practice
por: Pacchioni, F., et al.
Publicado: (2022)

Intranasal Esketamine administration in catatonia: a case report.
por: Romay, J., et al.
Publicado: (2023)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
por: Faisant, S., et al.
Publicado: (2022)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

The cognitive effects of esketamine: what do we know so far?
por: Barbosa, M., et al.
Publicado: (2022)

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode
por: Basto, M. D. R. D. R. F. D. A., et al.
Publicado: (2023)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Esketamine clinical trials: reply to Maju et al.
por: Gastaldon, C., et al.
Publicado: (2020)

Gender differences in response and remission rates among patients receiving esketamine
por: Guterman, A. T., et al.
Publicado: (2023)

Mental health services for mood disorder outpatients in Milan during COVID-19 outbreak: The experience of the health care providers at San Raffaele hospital
por: Franchini, Linda, et al.
Publicado: (2020)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

A blemish on bipolar disorder: aggressive behaviour
por: Zanardi, R., et al.
Publicado: (2022)

Resistance or pseudo-resistance?
por: Zanardi, R., et al.
Publicado: (2022)

Research advances in the clinical application of esketamine
por: Zhang, Xiao‐Xi, et al.
Publicado: (2022)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Adjunctive short- and long-term combination treatment of esketamine and VNS in difficult to treat depression (DTD)
por: Kavakbasi, E., et al.
Publicado: (2023)

Efficacy of maintenance electroconvulsive therapy in recurrent depression: a case series
por: Guerra Valera, G., et al.
Publicado: (2023)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis
por: Samalin, L., et al.
Publicado: (2023)

Safety and efficacy of esketamine for postoperative analgesia in pediatric patients with hypospadias
por: Xu, Yong, et al.
Publicado: (2023)

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
por: Vázquez, Gustavo H., et al.
Publicado: (2021)

Efficacy and tolerability of brexpiprazole in patients with psychotic and mood disorders: a pilot study
por: Civardi, S.C., et al.
Publicado: (2022)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

1642. Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data
por: Aslam, Saima, et al.
Publicado: (2018)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine
por: Dadiomov, David
Publicado: (2020)

Unsupervised neurobiology-driven stratification of clinical heterogeneity in depression
por: Colombo, F., et al.
Publicado: (2023)

2287. Real-world Use of Tedizolid Phosphate: A Case Series of Long-Term Tolerability
por: Morrisette, Taylor, et al.
Publicado: (2019)

1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series
por: Freeman, Kennedy J, et al.
Publicado: (2021)

Efficacy of Analgesic Propofol/Esketamine and Propofol/Fentanyl for Painless Induced Abortion: A Randomized Clinical Trial
por: Xin, Naixing, et al.
Publicado: (2022)

Efficacy and Safety of Esketamine for Supplemental Analgesia During Elective Cesarean Delivery: A Randomized Clinical Trial
por: Xu, Li-Li, et al.
Publicado: (2023)

Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression
por: Lan, Xiaofeng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lefupe4ruou61bi4qqn3qo7gga